157 results about "Enterocyte" patented technology

The invention provides lactobacillus plantarum resistant to enteritis salmonella infection and the application thereof and belongs to the technical field of microorganisms.The lactobacillus plantarum is preserved in the China General Microbiological Culture Collection Center (CGMCC) on Sep, 24th, 2015 with the preservation number of CGMCC No.11446.The lactobacillus plantarum CGMCC No.11446 has high acid and cholate resistance, and has a remarkable inhibition effect on growth of enteritis salmonella.Adhesion of enteritis salmonella to enterocyte HT-29 is strongly inhibited, and enteritis salmonella infection is prevented or relieved.The lactobacillus plantarum CGMCC No.11446 can be used for preparing pharmaceutical compositions for preventing or relieving enteritis salmonella, food containing activity lactobacillus and fermented food, and has broad application prospects.

The invention discloses a protein sequence which has a sequence shown as a SEQIDNo.1 in an amino acid list. The protein sequence can be applied to medicines and medicaments for protecting enterocyte. A medicine containing the protein sequence is provided. The protein sequence in SLP originated from lactobacillus plantarum is applied to medicines and medicaments for protecting enterocyte. The medicine containing the sequence is further disclosed. The protein sequence has the positive effect of protecting enterocyte and has no side effect to human body.

The invention provides drug composition of oral rehydration salt and a preparation method of the drug composition. The composition comprises main components including sodium chloride, potassium chloride or potassium citrate, sodium citrate, zinc gluconate, albumin tannate and anhydrous glucose. The drug composition of oral rehydration salt can be used for protecting and repairing intestinal mucosa, promoting regeneration of intestinal epithelial cells and reducing secretion of water and electrolyte by the intestinal mucosa, exudation is reduced, and stimulation and intestine peristalsis are relieved.

The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.

The invention relates to an oridonin cubic liquid crystal nanoparticle and a preparation method thereof. The oridonin cubic liquid crystal nanoparticle is prepared from the following raw materials in percentage by weight: 0.1 to 0.5 percent of oridonin, 7 to 64 percent of amphiphilic lipid material, 6 to 29 percent of solvent, 1 to 8 percent of stabilizer, and 25 to 65 percent of water, wherein the amphiphilic lipid material is glycerol mono-oleate or phytould likeriol; the mass ratio of a liquid crystal material to the stabilizer is 1 to (0.01 to 0.30). The oridonin cubic liquid crystal nanoparticle provided by the invention is smaller in particle size, good in uniformity, and beneficial to endocytosis and transfer of enterocyte; by utilizing a unique structure of cubic liquid crystal, a dissolution barrier and a permeation barrier of the oridonin during an oral absorption process are effectively overcome, the oral relative bioavailability of the oridonin is remarkably improved, and meanwhile, the oridonin can be slowly released.

The invention relates to a streptococcus faecium function signal molecule preparation, a streptococcus faecium bacteria strain is carried out the anaerobic fermentation at 35 to 38 DEG C and the centrifugal concentration to obtain a concentrate of streptococcus faecium bacteria, the bacterial cell wall is broken by high pressure, and the freeze-drying is carried out to obtain the preparation raw powder containing the streptococcus faecium function signal molecules. As the streptococcus faecium function signal molecules can be combined with a specific receptor at the intestinal epithelial cells, the issued signal can induce the excessive cholesterol in the body to carry out the transformation, control the activity of the cholesterol synthase, reduce the excessive cholesterol generated or absorbed in the human body, and effectively control the obesity. The streptococcus faecium function signal molecule preparation is simultaneously matched with a bifidobacterium function signal molecule preparation, a lactobacillus function signal molecule preparation and a bacteroides function signal molecule preparation to be prepared into a series of products containing various probiotics function signal molecules for lipid-lowering and weight-losing, thus fundamentally reducing the risks of coronary heart disease, atherosclerosis, heart diseases, angina, myocardial infarction, obesity and other diseases during the process of being eaten by the people.

The invention discloses a solid dispersion body of a berberine-phospholipid complex and a preparation method thereof and belongs to the field of pharmaceuticals. The lipid solubility of berberine is low, the absorbing capability of a permeable membrane is poor, and the berberine is a substrate of P-glycoprotein (P-gp) and is expelled by epithelial cells on the stomach and intestine to result in the extremely low oral bioavailability, so that an effective method needs to be adopted to improve the lipid solubility of the berberine, meanwhile, the expelling of P-glycoprotein is inhibited, and further the drug absorption is promoted. The solid dispersion body of the berberine-phospholipid complex disclosed by the invention consists of berberine, phospholipid, vitamin E polyethylene glycol succinic acid ester and silicon dioxide in a certain weight ratio, and has the advantages that the lipid solubility of the berberine is improved, the expelling of P-glycoprotein is inhibited, the drug is promoted to be absorbed by the gastrointestinal tract, the bioavailability is improved, the stability and the flowability are good, the preparation method is simple and convenient, and the great industry prospect is provided.

A method of making a live cell construct is carried out by: (a) providing a non-cellular support having a top surface and a bottom surface, (b) contacting live undifferentiated cells to the non-cellular support, and then (c) propagating a gastrointestinal epithelial cell monolayer on said top surface. In some embodiments, the live cells in the monolayer include: (i) undifferentiated cells (e.g., stem or progenitor cells); and (ii) optionally, but in some embodiments preferably, differentiated cells (e.g., enterocytes, Paneth cells, enteroendocrine cells, tuft cells, microcells, intra-epithelial lymphocytes, and/or goblet cells). Constructs formed by such methods and methods of using the same (e.g., in high through-put screening) are also described.

The invention discloses application of 4', 5, 7-genistein in preparing rotavirus resisting medicine. The genistein can restrain damage of tyrosine protein kinase to cell junction by restraining activation, caused by rotavirus infection, of tyrosine protein kinase of intestinal epithelial cells, so that the intestinal epithelial cells are prevented from being damaged by rotavirus, the completeness of intestinal mucosa is protected, the symptom of rotavirus diarrhea is obviously reduced, and the lethality is reduced. Thus, when the genistein is used as a main active ingredient, high-efficient and low-toxicity specificity rotavirus diarrhea resisting medicine can be researched and developed hopefully.

The invention belongs to the field of food production, and particularly relates to an enteral nutrition preparation capable of protecting intestinal mucosal barrier function injured by chemotherapy. The nutrition preparation contains oyster polysaccharides. The oyster polysaccharides are prepared by the following steps: washing oyster meat, homogenating, adding water for performing ultrasonic treatment, adding protease for performing enzymolysis, then adding ethanol for precipitating to obtain oyster polysaccharides. The oyster polysaccharides component which have obvious activities of resisting oxidization, enhancing immunity and promoting proliferation of intestinal epithelial cells are screened through cell activity, are used as immune nutrients to be applied to enteral nutrition preparation, and are used for development of an enteral nutrition preparation capable of recovering and maintaining the intestinal mucosal barrier function injured by chemotherapy and improving prognosis of tumor patients. According to the enteral nutrition preparation, the nutrient substances are reasonably proportioned according to the physiological metabolism of the tumor patients so as to design and develop the enteral nutrition preparation which has the effects of recovering and maintaining the intestinal mucosal barrier function injured by chemotherapy and improving the prognosis of tumor patients.

The invention discloses an inactivation type fermented milk beverage with an immunological regulation function and a preparation method of the inactivation type fermented milk beverage. The inactivation type fermented milk beverage with certain intestine clearing function and immunological regulation function is prepared by taking fresh milk, marine polysaccharide, fructooligosaccharide and lactobacillus paracasei N1115 as raw materials; the fermented milk beverage can be used for enhancing the immunity activity of epithelial cells and macrophages of intestines and also contains phenyllactic acid (PLA) with bacterium inhibiting activity, so that pathogenic bacteria are prevented from being colonized in the intestines and the fermented milk beverage has certain intestine clearing effect.

The present invention discloses novel nucleic acid sequences which are implicated in the growth regulation of the epithelial cells of the colon, and which sequences are differentially expressed in cancerous colon tissues compared to normal colon tissues. These sequences are useful in diagnosing abnormal cell growth, treatment of abnormal cell growth and screening assays for, treatments of abnormal cell growth.

An agent for relieving intestinal disorders which contain live cells of a strain belonging to Lactobacillus helveticus. This strain is preferably characterized by a resistance to a specific bile acid, adhesiveness to intestinal epithelial cells, etc. A method of controlling intestinal functions which involves the step of administering such a medicine to a subject with a need for the control of intestinal functions. When administered to humans or the like, these agents exert effects of elevating defecation frequency, etc., thereby efficaciously improving the intestinal environment.

The invention relates to the field of biotechnologies, in particular to a small molecular polypeptide. The polypeptide is provided with an amino acid sequence shown as SEQ ID NO:1. The invention further provides application of the small molecule polypeptide in preparation of drugs for treating colitis and colorectal cancers related to colitis. The colon length, tumor number and the like of a treatment group of rats are obviously lower than those of a control group through treatment of the small molecular polypeptide. The bowel tissue proliferation indexes of rats suffering from the colorectal cancers related to colitis are remarkably reduced. In addition, the small molecular polypeptide can promote enterocyte apoptosis and inhibit enterocyte proliferation in an in-vitro cell experiment. The purpose of blocking inflammatory-cancer conversion is achieved by interfering or blocking biological functions of the polypeptide FKBP11, and novel drug design and a therapeutic target are provided for relieving of colitis related tumors.

The invention discloses coptisine derivatives, a synthesis method thereof, and application of the coptisine derivatives to preparation of products for preventing, relieving and/or treating tumor products. The coptisine derivatives are an 8-iminodihydrogen coptisine derivative and a N-dihydrogen coptisine-8-imino derivative which are as shown in a general formula I as well as an 8-N,N-disubstituted amino coptisine quaternary ammonium salt derivative and an 8-N,N-disubstituted amino-13-substituted coptisine quaternary ammonium salt derivative which are as shown in a general formula II. The coptisine derivatives have inhibitory activity on the growth of tumor cell strains, and the effect intensity of the coptisine derivatives is obviously higher than that of coptisine quaternary ammonium salt raw materials or equal to that of a positive control medicine or higher than that of a positive control medicine; part of the compounds does not show remarkable cytotoxicity on IEC-6 enterocyte; the coptisine derivatives can be applied to preparation of the products for preventing, relieving and/or treating tumor.

The invention discloses a method for screening a live pig intestinal micro-ecological preparation with high adhesive capacity. The method comprises the following steps: culturing pig manure by adopting a chemostat, picking microorganisms adhered to a bottle wall of the chemostat, performing identification, and then evaluating the influences of the microorganisms on the adhesive capacity of intestinal epithelial cells HT-29 and the influences of different factors (temperature, cholate, PH values and the like) on the growth of screened bacteria. The method disclosed by the invention has the advantages as follows: the method directly adopts the adhesive capacity on the bottle wall of the chemostat as a screening indicator, and has strong pertinence. Because the adhesive capacity is a key indicator for probiotics to play roles, the method can be used for screening micro-ecological potential strains of animal husbandry and human beings.

The invention provides a method for evaluating the biosecurity of 76 nm nano silver on the base of intestinal epithelial cells. According to the method, cell lines of human colon carcinoma epithelial cells Caco-2 are selected as an object of study, nano zinc oxide (90.81 nm) with higher cytotoxicity is taken as a positive control, normal cells without the nano material are taken as a blank control, and the cytotoxicity of the nano material is preliminarily explored by an AO/EB double staining method and a CCK-8 method. The oxidative damage effect and the possible mechanism of nano silver on cells are studied by an oxidative stress method through detecting the influence of emission of ROS, SOD and GSH in the cells Caco-2. The result shows that 76.29nm silver particles (smaller than 200 mu g/ml) don't influence the activity of the cells Caco-2 obviously and cause no oxidative stress damage on the cells Caco-2, but the oxidation resistance of the cells is enhanced and is up to the highest level when the concentration of nano silver is 50 mu g/ml.

The invention belongs to the field of biomedicines and particularly relates to specific polypeptide targeting at human colon cancer cells and the application of the polypeptide. The polypeptide is anyone of the following components: (1) polypeptide with an amino acid sequence as: YPEIWPTDHKLM (SEQ ID No.1); (2) a polypeptide derivative which is formed by deleting, inserting or replacing one or more amino acids of polypeptide molecules of the polypeptide (1) and has biological functions same as those of the polypeptide molecules of the polypeptide (1). The polypeptide is capable of being specifically combined with colon cancer cells, has no specific action with normal enterocyte, and in addition is remarkable in action effect, and reliable scientific bases can be provided for clinical treatment.